TuHURA Biosciences (HURA) said Monday that it has completed its acquisition of Kineta.
TuHURA said Kineta shareholders received 2.87 million TuHURA shares and may receive up to 1.13 million additional shares based on post-closing adjustments. They are also eligible for a portion of future cash from legacy Kineta asset sales, TuHURA said.
TuHURA said the acquisition adds a mid-stage Vista inhibiting monoclonal antibody to its late-stage immuno-oncology pipeline.
TuHURA said it plans to start a mid-stage randomized trial in H2 using the Vista inhibiting antibody.
TuHURA said the completion of the deal also resulted in the release of the fourth tranche of funds from a $12.5 million PIPE financing reported earlier this month.
Shares of the company were up 5% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.